| Range | 6M |
|---|---|
| First date | — |
| Last date | — |
| Open | — |
| High | — |
| Low | — |
| Close | — |
| Volume | — |
| Plotted bars | 0 |
Event records
Event records load after the price chart.
Healthcare · Biotechnology
The Quantellect read. ABOS fell 15.65% in the Nov 18 session to $0.19, which is 94.2% below its 52-week high of $3.37. Short interest is 12.30% of float with a 0.35% borrow fee. Two active firms cover the stock as of Nov 19, 2026; two active firms with targets average $6.50 over 12 months. Descriptive summary of the data on this page, not a recommendation.
—
RSI (14) 21.7 (overbought above 70, oversold below 30)
—
FINRA settlement Oct 30, 2026
Price $0.19 · As of Nov 18, 2026, 3:59 PM ET
| Range | 6M |
|---|---|
| First date | — |
| Last date | — |
| Open | — |
| High | — |
| Low | — |
| Close | — |
| Volume | — |
| Plotted bars | 0 |
Event records load after the price chart.
| Range | 6M |
|---|---|
| First close | — |
| Last close | — |
| High | — |
| Low | — |
| Volume | — |
ABOS · NASDAQ · USD
Split-adjusted · volume in shares
— · Notable price movement not available
— · Options flow not available
Insufficient data · Tide session Nov 18, 2026
— · Industry comparison not available
Insufficient coverage
Based on 2 active firms as of Nov 19, 2026 (365-day activity window)
As of Nov 19, 2026 across 2 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →In the last 60 days: 0 insider sales and 0 purchases. No congressional trades in 90 days.
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with
Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.